Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × INDUSTRY × urelumab × Clear all

Phase

Phase 1 8 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

pembrolizumab 202 Carboplatin 116 Gemcitabine 102 Nivolumab 100 Paclitaxel 98 Cisplatin 81 Bevacizumab 81 Cyclophosphamide 75 Injections 58 Docetaxel 58 Dexamethasone 58 Pemetrexed 56 Capecitabine 53 Rituximab 52 atezolizumab 51 Fluorouracil 51 Cetuximab 50 130-nm albumin-bound paclitaxel 49 Oxaliplatin 46 Leucovorin 41 venetoclax 37 Ipilimumab 37 Lenalidomide 36 Azacitidine 35 fludarabine 32 Trastuzumab 31 Irinotecan 31 Fulvestrant 30 Prednisone 29 Albumin-Bound Paclitaxel 29

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00309023 2015-10-12

Study of BMS-663513 in Patients With Advanced Cancer

Bristol-Myers Squibb

Phase 1/2 Terminated

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡